Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

• Status: RECRUITING
• Trial end date: 2027-04-01

Summary

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

• Phase: PHASE3

Details

• Lead Sponsor: Celltrion
• Treatments: alogliptin; empagliflozin; Metformin